In April 2025,Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis was published online in Gastroenterology.These recommendations address the areas with significant divergence,such as metabolic dysfunction-associated steatotic liver disease(MASLD)screening steps,the use of noninvasive tests for risk stratification,management of comorbidities,and the recent advances in resmetirom for the treatment of metabolic dysfunction-associated steatohepatitis(MASH),covering the most debated topics in current MASLD management.This article makes an excerpt of the main contents in these consensus recommendations.

Metabolic dysfunction-associated steatotic liver disease is the largest liver disease around the world and is a serious public health hazard， but there has always been a lack of drugs approved for treatment. On March 14， 2024， Resmetirom became the first drug approved by the US Food and Drug Administration for the treatment of metabolic dysfunction-associated steatohepatitis （MASH）. This article summarizes the mechanism of action of Resmetirom in the treatment of MASH， related clinical trial designs， and some research results and analyzes shortcomings and future prospects. Current data have shown that Resmetirom is effective in improving steatohepatitis and liver fibrosis， but there is still a large gap between Resmetirom and the ideal drug for the treatment of MASH， and it is expected to develop more effective drugs for MASH.

Objective To observe the correlation between fat fraction(FF)and T2 value of multifidus muscle and Pfirrmann grade of L4-5 intervertebral disc in patients with lumbar muscle strain.Methods Totally 200 L4_5 intervertebral discs in 200 patients with lumbar muscle strain were retrospectively enrolled,including 6 cases of Pfirrmann grade Ⅰ,61 of grade Ⅱ,52 of grade Ⅲ,56 of grade Ⅳ and 25 cases of grade V.Based on modified DIXON quantification(mDIXON-Quant)and T2 mapping,FF and T2 value of multifidus muscle were calculated and compared among intervertebral discs with different Pfirrmann grades,and the correlations between the above parameters and Pfirrmann grade of intervertebral disc were analyzed.Results Significant differences of left,right and bilateral multifidus muscles FF,as well as of T2 values in left and bilateral multifidus muscles were found among L4-5 intervertebral discs with different Pfirrmann grades.Multifidus muscle FF was moderately positively correlated with Pfirrmann grade of L4-5 intervertebral disc(r=0.538,P＜0.05),while T2 value was weakly positively correlated with Pfirrmann grade of L4-5 intervertebral disc(r=0.202,P＜0.05).Conclusion FF of multifidus muscle was moderately positively correlated with Pfirrmann grade of L4-5 intervertebral disc,while T2 value of multifidus muscle was weakly positively correlated with Pfirrmann grade of L4-5 intervertebral disc in patients with lumbar muscle strain.

In April 2025,Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis was published online in Gastroenterology.These recommendations address the areas with significant divergence,such as metabolic dysfunction-associated steatotic liver disease(MASLD)screening steps,the use of noninvasive tests for risk stratification,management of comorbidities,and the recent advances in resmetirom for the treatment of metabolic dysfunction-associated steatohepatitis(MASH),covering the most debated topics in current MASLD management.This article makes an excerpt of the main contents in these consensus recommendations.

Objective To observe the correlation between fat fraction(FF)and T2 value of multifidus muscle and Pfirrmann grade of L4-5 intervertebral disc in patients with lumbar muscle strain.Methods Totally 200 L4_5 intervertebral discs in 200 patients with lumbar muscle strain were retrospectively enrolled,including 6 cases of Pfirrmann grade Ⅰ,61 of grade Ⅱ,52 of grade Ⅲ,56 of grade Ⅳ and 25 cases of grade V.Based on modified DIXON quantification(mDIXON-Quant)and T2 mapping,FF and T2 value of multifidus muscle were calculated and compared among intervertebral discs with different Pfirrmann grades,and the correlations between the above parameters and Pfirrmann grade of intervertebral disc were analyzed.Results Significant differences of left,right and bilateral multifidus muscles FF,as well as of T2 values in left and bilateral multifidus muscles were found among L4-5 intervertebral discs with different Pfirrmann grades.Multifidus muscle FF was moderately positively correlated with Pfirrmann grade of L4-5 intervertebral disc(r=0.538,P＜0.05),while T2 value was weakly positively correlated with Pfirrmann grade of L4-5 intervertebral disc(r=0.202,P＜0.05).Conclusion FF of multifidus muscle was moderately positively correlated with Pfirrmann grade of L4-5 intervertebral disc,while T2 value of multifidus muscle was weakly positively correlated with Pfirrmann grade of L4-5 intervertebral disc in patients with lumbar muscle strain.

Purpose To evaluate the value of 18F-FDG PET/CT in the diagnosis of intradural metastasis.Materials and Methods The imaging data of patients with clinical suspicion of intraspinal metastasis who underwent 18F-FDG PET/CT and MRI of the whole spinal cord from October 2010 to April 2022 in Jiangxi Provincial People's Hospital were retrospectively analyzed.Visual evaluation was performed on the metabolic activity of the lesion and the maximum standard uptake value(SUVmax)was measured.The sensitivity,specificity and accuracy of 18F-FDG PET/CT in the diagnosis of intradural metastases were analyzed,and the efficacy of SUVmax in the diagnosis of intradural metastases was analyzed by receiver operating characteristic curve.Results Among 135 patients suspected of intraspinal metastasis,18 patients were diagnosed with intradural metastases,80 patients had other lesions and 37 patients had no metastasis.Among the 18 cases of intradural metastases,13 cases were leptomeningeal metastases,2 cases were intramedullary metastasis,3 patients had both leptomeningeal and intramedullary metastasis.Metastases appear as nodular(10 cases)or patchy(6 cases)increased fluorodeoxyglucose uptake,corresponding to paramedullary or intramedullary nodules or spinal cord swelling on CT.18F-FDG PET/CT showed more lesions than MRI,including subcentimeter foci.Based on patients,the sensitivity,specificity and accuracy of 18F-FDG PET/CT in diagnosing intradural metastasis were 88.9%,89.2%and 89.1%,respectively.The receiver operating characteristic curve analysis showed that when SUVmax was 2.45,Youden index was the largest,corresponding to 88.2%sensitivity and 75.7%specificity.Conclusion 18F-FDG PET/CT may be an optional imaging modality for diagnosis of intradural metastases.Most of the intradural metastases present with focal hypermetabolic lesions.SUVmax can be used as a valuable parameter in the diagnosis of intradural metastases.

In the context of the global epidemic of metabolic syndrome,the incidence of type 2 diabetes mellitus(T2DM)and metabolic dysfunction-associated steatotic liver disease(MASLD)is on the rise,with a close relationship between the two conditions.They often co-occur and are rapidly becoming a significant public health issue worldwide.In May 2024,the concept of"co-management of fatty liver and diabetes"was first introduced.To date,no approved medications for the treatment of T2DM combined with MASLD have been launched.This article reviewed the progress of MASLD treatment drugs within the"co-management of fatty liver and diabetes"model,providing clinical references for the treatment of T2DM combined with MASLD.

In the context of the global epidemic of metabolic syndrome,the incidence of type 2 diabetes mellitus(T2DM)and metabolic dysfunction-associated steatotic liver disease(MASLD)is on the rise,with a close relationship between the two conditions.They often co-occur and are rapidly becoming a significant public health issue worldwide.In May 2024,the concept of"co-management of fatty liver and diabetes"was first introduced.To date,no approved medications for the treatment of T2DM combined with MASLD have been launched.This article reviewed the progress of MASLD treatment drugs within the"co-management of fatty liver and diabetes"model,providing clinical references for the treatment of T2DM combined with MASLD.